Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

  • Awaiting development
  • GID-TA11775
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Fenebrutinib within its marketing authorisation for treating multiple sclerosis ID6577